全文获取类型
收费全文 | 23393篇 |
免费 | 6035篇 |
国内免费 | 129篇 |
专业分类
耳鼻咽喉 | 654篇 |
儿科学 | 745篇 |
妇产科学 | 746篇 |
基础医学 | 510篇 |
口腔科学 | 2901篇 |
临床医学 | 4321篇 |
内科学 | 5557篇 |
皮肤病学 | 515篇 |
神经病学 | 1950篇 |
特种医学 | 1113篇 |
外科学 | 4147篇 |
综合类 | 99篇 |
现状与发展 | 12篇 |
一般理论 | 1篇 |
预防医学 | 2786篇 |
眼科学 | 494篇 |
药学 | 297篇 |
中国医学 | 18篇 |
肿瘤学 | 2691篇 |
出版年
2024年 | 137篇 |
2023年 | 1103篇 |
2022年 | 398篇 |
2021年 | 712篇 |
2020年 | 1258篇 |
2019年 | 518篇 |
2018年 | 1383篇 |
2017年 | 1316篇 |
2016年 | 1557篇 |
2015年 | 1634篇 |
2014年 | 2054篇 |
2013年 | 2499篇 |
2012年 | 941篇 |
2011年 | 905篇 |
2010年 | 1491篇 |
2009年 | 2034篇 |
2008年 | 861篇 |
2007年 | 628篇 |
2006年 | 761篇 |
2005年 | 544篇 |
2004年 | 419篇 |
2003年 | 365篇 |
2002年 | 318篇 |
2001年 | 443篇 |
2000年 | 337篇 |
1999年 | 442篇 |
1998年 | 519篇 |
1997年 | 500篇 |
1996年 | 543篇 |
1995年 | 404篇 |
1994年 | 305篇 |
1993年 | 267篇 |
1992年 | 205篇 |
1991年 | 179篇 |
1990年 | 155篇 |
1989年 | 163篇 |
1988年 | 155篇 |
1987年 | 147篇 |
1986年 | 122篇 |
1985年 | 114篇 |
1984年 | 90篇 |
1983年 | 95篇 |
1982年 | 86篇 |
1981年 | 71篇 |
1980年 | 51篇 |
1979年 | 42篇 |
1978年 | 38篇 |
1977年 | 48篇 |
1976年 | 35篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
6.
Aditya Kelkar Caroll Webers Rohit Shetty Jai Kelkar Nikhil Labhsetwar Abhishek Pandit Madhulika Malode Sayali Tidke 《Indian journal of ophthalmology》2020,68(10):2143
Purpose:To evaluate the rate of compliance and the reasons for loss to follow-up in Indian patients with diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) being treated with anti-vascular endothelial growth factor (VEGF) therapy.Methods:This was a retrospective single-center study. Patients with DME, AMD, or RVO were eligible if they initiated anti-VEGF therapy between January 2013 and December 2017. Patients'' data were obtained from hospital electronic records, including the number of injections received, visits, details of follow-up, missed appointments, and reasons for loss to follow-up (>365 days).Results:A total of 648 patients were eligible for the study, of which 334 (51.54%) patients were lost to follow-up. Overall, 343 (64.96%) were males and the overall mean (SD) age was 66.40 (7.44) years. A total of 376 (58.0%) patients had a history of diabetes and 364 (56.2%) patients had a history of hypertension. Further, 127 (38.0), 112 (33.5), and 95 (28.4) had DME, AMD, and RVO, respectively and were lost to follow-up. The most commonly reported reason for loss to follow-up was “non-affordability” (n = 120; 41.1%) followed by “no improvement in vision” (n = 83; 28.4%). “No improvement in vision” (42.2%) and “non-affordability” (37.5%) were higher among patients with DME. No association was found in gender- and treatment-wise distribution of reasons for loss to follow-up.Conclusion:The results showed that around half of the patients with DME, AMD, and RVO were lost to follow-up to intravitreal anti-VEGF therapy, and the most common factors were “non-affordability” and “no improvement in vision.” 相似文献
7.
8.
9.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
10.